학술논문
3-year invasive disease-free survival with chemotherapy de-escalation using an 18 F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial
Document Type
Article
Author
Pérez-García, J.M.; Cortés, J.; Popa, C.; Szostak, E.; Alcalá-López, D.; Gener, P.; Rodríguez-Morató, J.; Mina, L.; Sampayo-Cordero, M.; Llombart-Cussac, A.; Ruiz-Borrego, M.; Colleoni, M.; Stradella, A.; Bermejo, B.; Dalenc, F.; Escrivá-de-Romaní, S.; Calvo Martínez, L.; Ribelles, N.; Marmé, F.; Cortés, A.; Gion, M.; Albacar, C.; Gebhart, G.; Prat, A.; Kerrou, K.; Schmid, P.; Braga, S.; Di Cosimo, S.; Antonarelli, G.
Source
In: The Lancet . (The Lancet, 27 April 2024, 403(10437):1649-1659)
Subject
Language
English
ISSN
1474547X
01406736
01406736